| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 7.280.517 | 14.079.284 | 13.597.941 | 15.162.100 | 13.827.399 | 10.512.304 | 12.581.898 | 14.146.567 | 16.381.921 | 17.588.772 |
| Total Income - EUR | 7.301.443 | 14.115.775 | 13.645.883 | 15.196.238 | 13.883.954 | 10.538.951 | 12.600.796 | 14.168.860 | 16.403.588 | 17.686.139 |
| Total Expenses - EUR | 6.789.945 | 13.179.216 | 12.866.010 | 14.092.349 | 13.115.446 | 10.234.422 | 11.985.212 | 13.300.036 | 15.560.461 | 16.673.034 |
| Gross Profit/Loss - EUR | 511.497 | 936.559 | 779.873 | 1.103.890 | 768.508 | 304.528 | 615.584 | 868.824 | 843.127 | 1.013.106 |
| Net Profit/Loss - EUR | 430.051 | 791.555 | 615.598 | 919.849 | 643.877 | 249.381 | 513.990 | 730.188 | 708.990 | 869.312 |
| Employees | 9 | 10 | 14 | 16 | 16 | 18 | 18 | 18 | 19 | 19 |
Check the financial reports for the company - Rubicon Pharmaceuticals Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 193.365 | 233.787 | 1.109.422 | 1.138.610 | 2.103.679 | 2.025.802 | 1.849.338 | 1.855.146 | 1.856.908 | 1.907.036 |
| Current Assets | 1.950.139 | 2.479.280 | 2.561.034 | 4.060.626 | 2.439.290 | 4.316.185 | 4.301.293 | 4.493.357 | 6.587.073 | 5.919.081 |
| Inventories | 177.649 | 445.032 | 1.391.748 | 1.862.922 | 676.476 | 2.450.141 | 1.233.177 | 1.759.670 | 2.979.610 | 2.347.981 |
| Receivables | 1.504.355 | 1.902.684 | 999.280 | 2.063.841 | 1.656.813 | 1.609.438 | 2.947.198 | 2.690.049 | 3.566.650 | 3.410.850 |
| Cash | 268.135 | 131.563 | 170.006 | 133.863 | 106.000 | 256.605 | 120.917 | 43.638 | 40.814 | 160.250 |
| Shareholders Funds | 430.510 | 1.063.747 | 878.289 | 1.537.137 | 1.677.859 | 1.663.792 | 1.877.215 | 1.664.640 | 2.365.987 | 2.676.389 |
| Social Capital | 450 | 222.677 | 218.909 | 214.892 | 632.191 | 826.942 | 808.604 | 811.112 | 808.653 | 804.133 |
| Debts | 1.715.258 | 1.651.136 | 2.794.385 | 3.664.079 | 2.868.144 | 4.684.692 | 4.277.777 | 4.689.333 | 6.087.594 | 5.176.567 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Rubicon Pharmaceuticals Srl